Welcome to the European Association for Cancer Research
Connecting cancer researchers together
Cellular Bases for Patient Response to Cancer Therapies
Lyon, France : 14 - 16 November 2023
Scientific Programme
To download and print the programme, use the links below.
Listed times are in Central European Time (CET)
REGISTRATION & WELCOME LUNCH (lunch from 12:00)
WELCOME TO DAY ONE
SESSION 1 - Technologies and Genomics
Chair: Sophie Postel-Vinay
Opening Keynote Lecture
Scott Lowe Memorial Sloan Kettering Cancer Centre, New York, USA
"Understanding and exploiting tumor suppressive programs"
Q&A: 13:45-13:55
Céline Vallot Institut Curie, Paris, France
"Mechanisms of cell plasticity in breast cancers"
Q&A: 14:15-14:25
Mirja Rotinen Public University of Navarre, Pamplona, Spain
Proffered Paper 1: "ONECUT2 is a targetable lineage plasticity modulator of breast cancer that suppresses the estrogen axis"
Q&A: 14:35 - 14:40
EXHIBITOR INTRODUCTIONS
COFFEE BREAK & EXHIBITION
Jean Soulier Hôpital Saint-Louis, INSERM, Paris, France
"Secondary leukemia to stressed hematopoiesis"
Q&A: 15:40-15:50
Renata Basto Institut Curie, Paris, France
"Centrosome amplification induces apoptotic priming and favors the response to chemotherapy in epithelial ovarian cancer beyond multipolar divisions"
Q&A: 16:10-16:20
POSTER SPOTLIGHTS
Valeria Bica, University of Rome "Tor Vergata", Rome, Italy; Oriol de Barrios Barri, Josep Carreras Leukemia Research Centre, Barcelona, Spain; Naoyuki Nishiya, Iwate Medical University School of Pharmacy, Shiwa-gun, Japan
Meet The Expert Session
Yves Pommier, National Cancer Institute, Center for Cancer Research, Bethesda, USA; Céline Vallot, Institut Curie, Paris, France
WELCOME RECEPTION
POSTER DISCUSSION SESSION 1
Listed times are in Central European Time (CET)
EARLY POSTER VIEWING
Session 2: Leukemia Therapy
Chair: Patrick Mehlen
Andreas Trumpp German Cancer Research Centre (DKFZ), Heidelberg, Germany
"MAC-scoring in leukemic stem cells predicts response to Venetoclax in AML patients"
Q&A: 09:20-09:30
Irina Korovina HZDR – Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
Proffered Paper 2: "Integrin α2-deficiency reduces treatment resistance in glioblastoma by modulating ATF1 activity"
Q&A: 09:40 - 09:45
Hugues de Thé College de France, Paris, France
"From nuclear architecture to leukemia cure: emerging roles of PML"
Q&A: 10:05-10:15
Yves Pommier National Cancer Institute, Center for Cancer Research, Bethesda, MA, USA
"Genomics and Schlafen 11 (SLFN11) as predictors in oncology clinical trials"
Q&A: 10:35-10:45
COFFEE BREAK & EXHIBITION
Julien Ablain CRCL, Lyon, France
"Investigating the mechanisms of melanoma development and therapy response using zebrafish"
Q&A: 11:35-11:45
Laura Broutier CRCL, Lyon, France
Proffered Paper 3: "Modelling the next-generation of fusion-negative rhabdomyosarcoma 3D-organoids to predict effective drug combinations: a proof-of-concept on cell death inducers"
Q&A: 11:55 - 12:00
POSTER SPOTLIGHTS
Emmanuel Griessinger, Université Côte d'Azur, INSERM, Menton, France; Thi Nhat Uyen Nguyen, Taipei Medical University, Taipei, Taiwan; Sean Rudd, Karolinska Institutet, Solna, Sweden
LUNCH & EXHIBITION
POSTER DISCUSSION SESSION 2
Session 3: Novel Approaches to Drug Sensitivity
Chair: Hugues de The
Sophie Postel-Vinay IGR, Paris, France
"Harnessing genetic vulnerabilities in immuno-oncology: novel therapeutic opportunities"
Q&A: 15:00-15:10
Mattia Marinucci University of Basel, Basel, Switzerland
Proffered Paper 4: "(Phospho)Proteomic analysis reveals vulnerabilities in metastatic colorectal cancer"
Q&A: 15:20 - 15:25
Hyunbin Huh Yonsei, Seoul, South Korea
Proffered Paper 5: "Reprogramming anchorage dependency by adherent-to-suspension transition promotes metastatic dissemination"
Q&A: 15:35 - 15:40
Patrick Mehlen Lyon Cancer Research Center (CRCL), Paris, France
"Targeting netrin-1 in cancer: from mechanisms of cell death to patients"
Q&A: 16:00-16:10
COFFEE BREAK & EXHIBITION
Fanny Jaulin Gustave Roussy, Villejuif, France
"Organoids as tools for functional precision medicine in advanced pancreatic cancer"
Q&A: 17:00-17:10
The EMBO Keynote Lecture
Cedric Blanpain Laboratory of Stem Cells and Cancer, ULB, Brussels, Belgium
"Targeting EMT mediated resistance to therapy"
Q&A: 17:30-17:40
Panel Discussion
Chair: Hugues de The
Sophie Postel-Vinay, IGR, Paris, France; Patrick Mehlen, CRCL, Paris, France; Fanny Jaulin (Gustave Roussy, Villejuif, France
CONFERENCE DINNER
The 3-course dinner will be at the Hotel Crowne Plaza Lyon's restaurant, Antipasto. Optional ticketed event.
Listed times are in Central European Time (CET)
EARLY POSTER VIEWING
Session 4: Metabolism and Senescence
Chair: Sophie Postel-Vinay
Filipe Cabriero MRC London Institute of Medical Sciences, London, UK
"Microbially derived adjuvants for cancer chemotherapy"
Q&A: 09:20-09:30
Jean-Emmanuel Sarry Centre de Recherches en Cancérologie de Toulouse (Oncopole), Toulouse, France
"Metabolic bases of drug resistance in acute myeloid leukemia"
Q&A: 09:50-10:00
Rocio Matesanz Sanchez OncoRay – National Center for Radiation Research in Oncology, Dresden, Germany
Proffered Paper 6: "Targeting exostosin glycosyltransferase 2 (EXT2) modulates glioblastoma cell metabolism, sensitizing to X-ray irradiation via ferroptosis"
Q&A: 10:10 - 10:15
COFFEE BREAK & EXHIBITION
Geraldine Gentric Institut Curie, Paris, France
"Role of stromal heterogeneity in resistance to treatments"
Q&A: 11:05-11:15
Closing Keynote - Clemens Schmitt Max Delbruck Center, Berlin, Germany
"Apoptosis-competent anticancer treatment failure"
Q&A: 11:50-12:00
SUMMARY & CLOSE
Key dates
Travel Grant application deadline:
19 September 2023
Abstract submission deadline:
19 September 2023
Registration and Payment deadline:
17 October 2023
Keynote Lecture Sponsor
